Content » Vol 84, Issue 6

Clinical Report

Terbinafine-induced Subacute Cutaneous Lupus Erythematosus

David A. McKay , Olivia M.V. Schofield , E. Claire Benton
DOI: 10.1080/00015550410018361


Oral terbinafine is licensed for use in onychomycosis after positive confirmation of infection. We describe five cases of subacute cutaneous lupus erythematosus associated with terbinafine therapy. All cases had positive antibodies to extractable nuclear antigens, predominantly anti-Ro, and several had a history of pre-existing autoimmune disease. Terbinafine should only be prescribed after confirmation of infection by microscopy or culture.


Supplementary content


Not logged in! You need to login/create an account to comment on articles. Click here to login/create an account.